GlassScriptPhysician profile
Dale P Wicker
NPI 1215158977
$2,620.28
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,449 · 2022: $1,121 · 2023: $50.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $632.32 | 2021-2022 | |
| Lilly USA, LLC | $379.51 | 2021-2023 | Mounjaro |
| Abbvie INC. | $284.69 | 2021-2023 | |
| Novo Nordisk INC | $239.88 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.86 | 2021-2023 | |
| Amgen INC. | $131.53 | 2021-2022 | |
| Pfizer INC. | $112.44 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.37 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $100.76 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $65.38 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $53.40 | 2021 | |
| Daiichi Sankyo INC. | $50.39 | 2021-2022 | |
| Abbott Laboratories | $44.91 | 2022 | |
| Kaleo, INC. | $43.24 | 2021 | |
| Janssen Pharmaceuticals, INC | $41.50 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.40 | 2022 | |
| Lundbeck LLC | $27.80 | 2022 | |
| Si-Bone, INC. | $19.93 | 2022 | |
| Amarin Pharma, INC. | $15.28 | 2022 | |
| Tris Pharma INC | $14.85 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.58 | 2021 | |
| Mylan Specialty L.P. | $13.16 | 2022 | |
| Merck Sharp & Dohme LLC | $13.16 | 2021 | |
| Dexcom, INC. | $12.38 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.17 | 2022 | |
| Genentech USA, INC. | $8.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Wicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.